NCT04351126View on ClinicalTrials.gov

Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response

PHASE2CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

February 25, 2020

Study Completion Date

February 29, 2020

Conditions
Ovarian Hyperstimulation Syndrome
Interventions
DRUG

Fludrocortisone 0.1 Milligrams (mg)

0.2-0.6 mg/day of fludrocortisone is prescribed

DRUG

Bromocriptine

2.5 mg prescribed Vaginally twice daily

Trial Locations (1)

11728

Ganin Fertility Center, Cairo

All Listed Sponsors
lead

Ganin Fertility Center

OTHER

NCT04351126 - Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response | Biotech Hunter | Biotech Hunter